Adult Dosing
Bacterial infections (tablets; suspension)
- 500/125 mg (amoxicillin/clavulanate) PO bid; alt: 250/125 mg (amoxicillin/clavulanate) PO tid
- Severe infections and infections of the respiratory tract: 500/125 mg (amoxicillin/clavulanate) PO tid or 875/125 mg (amoxicillin/clavulanate) PO bid
- In adults with swallowing difficulty, give 125 mg/5 mL or 250 mg/5 mL instead of 500-mg tablet; 200 mg/5 mL or 400 mg/5 mL instead of 875-mg tablet
Community-acquired pneumonia (ETABS)
- 2 tabs (amoxicillin 1000/clavulanic acid 62.5 mg ) PO bid x 7-10 days
Acute bacterial sinusitis (ETABS)
- 2 tabs (amoxicillin 1000/clavulanic acid 62.5 mg ) PO bid x 10 days
Bronchiectasis [Not FDA Approved]
- 875/125 mg (amoxicillin/clavulanate) PO q12 hrs or 500/125 mg (amoxicillin/clavulanate) PO q8 hrs
Peritonsillar abscess [Non-FDA Approved]
- 875/125 mg (amoxicillin/clavulanate) PO bid; In adults with swallowing difficulty, can use liquid formula instead of tablet 250 mg/5 mL; 17.5ml PO bid
COPD exacerbation[Non-FDA Approved]
- 875/125 mg (amoxicillin/clavulanate) PO bid
Notes:- Tablets (250 mg or 500 mg) cannot be used to provide the same dosages as extended release tablets because the ETABS contain 62.5 mg of clavulanic acid, while the 250-mg and 500-mg TABS each contain 125 mg of clavulanic acid. Also, the ETABS provide an extended time course of plasma amoxicillin concentrations compared to immediate-release tablets
- To be taken at the start of a meal to enhance the absorption of amoxicillin and to minimize the potential for gastrointestinal intolerance
Pediatric Dosing
Bacterial infections
Less severe infections
- <3 months: 30 mg/kg/day PO divided bid, based on amoxicillin component
- >3 mo, <40 kg: 25 mg/kg/day PO divided bid, alt: 20 mg/kg/day divided tid, based on amoxicillin component
- >40 kg: 500/125 mg (amoxicillin/clavulanate) PO bid; alt: 250/125 mg (amoxicillin/clavulanate) PO tid
Otitis media, sinusitis, lower respiratory tract infections, and more severe infections
- <3 months: 30 mg/kg/day PO divided bid, based on amoxicillin component
- >3 mo, <40 kg: 45 mg/kg/day PO divided bid, alt: 40 mg/kg/day divided tid, based on amoxicillin component
- >40 kg: 500/125 mg (amoxicillin/clavulanate) PO tid or 875/125 mg (amoxicillin/clavulanate) PO bid
Bronchiectasis [Not FDA Approved]
3 months: 30 mg/kg/day PO divided bid, based on amoxicillin component- >3 mo, <40 kg: 45 mg/kg/day PO divided tid
40 kg: 875/125 mg (amoxicillin/clavulanate) PO bid; alt: 500/125 mg (amoxicillin/clavulanate) PO tid
Peritonsillar abscess [Non-FDA Approved]
- <3 months: 30 mg/kg/day PO divided bid, based on amoxicillin component
- >3 mo, <40 kg: 20-40 mg/kg/day PO divided bid, alt: 25-45 mg/kg/day divided tid, based on amoxicillin component
- >40 kg: 500/125 mg (amoxicillin/clavulanate) PO bid; alt: 250/125 mg (amoxicillin/clavulanate) PO tid
Pediatrics Pneumonia [Non-FDA Approved]
- >40 kg: 80–90 mg/kg/day PO divided bid
Note:- The 250-mg tablet contains 125 mg of clavulanic acid, whereas the 250-mg chewable tablet contains 62.5 mg of clavulanic acid. Therefore, the 250-mg tablet and the 250-mg chewable tablet should not be substituted for each other, as they are not interchangeable
- The 250-mg tablet should not be used until the child weighs at least 40 kg and more
- To be taken at the start of a meal to enhance the absorption of amoxicillin and to minimize the potential for gastrointestinal intolerance
[Outline]
Tablets and oral suspension
Extended release tablets
- Community-acquired pneumonia
- Acute bacterial sinusitis
Renal Dose Adjustment: (Based on CrCl)
Immediate release tablets; Suspension
- <30 mL/min: Avoid administration of 875-mg tablet
- 10-30 mL/min: 250 or 500 mg PO bid
- <10 mL/min: 250 or 500 mg PO qd
- Hemodialysis: 500 or 250 mg PO qd; give usual dose as supplement both during and at the end of dialysis
Extended release tablets
- <30 mL/min: Contraindicated
- >30 mL/min: Dose adjustments not defined
Hepatic Dose Adjustment
- Hepatic impairment: Caution advised
- History of amoxicillin/clavulanate associated hepatotoxicity: Contraindicated
See Supplemental Patient Information
- Serious and occasionally fatal hypersensitivity reactions have been reported with penicillin therapy, more likely in patients with a history of hypersensitivity to penicillin, cephalosporins, or multiple allergens. Take a detailed history regarding previous hypersensitivity reactions before initiating the therapy
- If an allergic reaction occurs, discontinue the drug and institute appropriate therapy. In case of serious anaphylactic reactions, provide immediate emergency treatment with epinephrine, oxygen, intravenous steroids and airway management including intubation
- Clostridium difficile associated diarrhea (CDAD) ranging from mild diarrhea to fatal colitis may occur with amoxicillin/clavulanate therapy as antibacterial agents alter the normal flora of the colon leading to overgrowth of C. difficile
- C. difficile produces toxins A and B which contribute to CDAD. Hypertoxin-producing strains cause increased morbidity and mortality since these infections can be refractory to antibiotic therapy and may require colectomy. Careful medical examination is necessary since CDAD may occur >2 months after administration of drug
- If CDAD is suspected or confirmed, discontinue the treatment; provide fluid and electrolyte management, protein supplementation along with antibiotics for C. difficile, and consider surgical evaluation as clinically needed
- Hepatic toxicity, usually reversible, has been reported with amoxicillin/clavulanate therapy; use cautiously in patients with evidence of hepatic dysfunction
- Patients with mononucleosis may develop an erythematous skin rash with ampicillin; do not administer ampicillin-class antibiotics to patients with mononucleosis
- Organ system functions, including renal, hepatic, and hematopoietic function should be assessed periodically if therapy is for longer than the drug is approved for administration
- Prescribing antibiotics in the absence of proven or strongly suspected bacterial infection increases the risk of development of drug-resistant bacteria
- Superinfections with mycotic or bacterial pathogens can occur with amoxicillin/clavulanate; discontinue therapy and/or institute appropriate therapy if such infections occur
Cautions: Use cautiously in
Supplemental Patient Information
- Advise patients to contact their physicians if they develop severe diarrhea or if the diarrhea lasts more than 2-3 days
Pregnancy Category:B
Breastfeeding: Amoxicillin/clavulanate is acceptable for use during breastfeeding. Monitor infants for adverse events such as restlessness, diarrhea, and rash, which may occur occasionally. If amoxicillin-clavulanic acid is required by the mother, it is not a reason to discontinue breastfeeding. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 17 February 2011). However, manufacturer advises caution.
US Trade Name(s)
- Augmentin
- Augmentin ES-600
- Augmentin XR
US Availability
amoxicillin/clavulanate (generic)
- TABS: 250 mg/125 mg
- TABS: 500 mg/125 mg
- TABS: 875 mg/125 mg
- CHEW TABS: 200 mg/28.5 mg
- CHEW TABS: 400 mg/57 mg
- ETABS: 1000 mg/62.5 mg
- PWDR for SUSP: [200 mg/28.5 mg]/5 mL
- PWDR for SUSP: [400 mg/57 mg]/5 mL
- PWDR for SUSP: [600 mg/42.9 mg]/5 mL
Augmentin (amoxicillin/clavulanate)
- TABS: 250 mg/125 mg
- TABS: 500 mg/125 mg
- TABS: 875 mg/125 mg
- PWDR for SUSP: [125 mg/31.25 mg]/5 mL
- PWDR for SUSP: [250 mg/62.5 mg]/5 mL
- CHEW TABS: 200 mg/28.5 mg
- CHEW TABS: 400 mg/57 mg
Augmentin XR (amoxicillin/clavulanate)
Augmentin ES-600 (amoxicillin/clavulanate)
- PWDR for SUSP: [600 mg/42.9 mg]/5 mL
Canadian Trade Name(s)
- Apo-Amoxi Clav
- Amoxi-Clav
- Clavulin
- Novo-Clavamoxin
- ratio-Aclavulanate
Canadian Availability
Amoxi-Clav (amoxicillin/clavulanate)
- TABS: 500 mg/125 mg
- TABS: 875 mg/125 mg
Apo-Amoxi Clav (amoxicillin/clavulanate)
- TABS: 250 mg/125 mg
- TABS: 500 mg/125 mg
- TABS: 875 mg/125 mg
- PWDR for SUSP: [125 mg/31.25 mg]/5 mL
- PWDR for SUSP: [250 mg/62.5 mg]/5 mL
- PWDR for SUSP: [400 mg/57 mg]/5 mL
Clavulin (amoxicillin/clavulanate)
- TABS: 500 mg/125 mg
- TABS: 875 mg/125 mg
- PWDR for SUSP: [125 mg/31.25 mg]/5 mL
- PWDR for SUSP: [200 mg/28.5 mg]/5 mL
- PWDR for SUSP: [250 mg/62.5 mg]/5 mL
- PWDR for SUSP: [400 mg/57 mg]/5 mL
Novo-Clavamoxin (amoxicillin/clavulanate)
Ratio-Aclavulanate (amoxicillin/clavulanate)
- TABS: 500 mg/125 mg
- TABS: 875 mg/125 mg
- PWDR for SUSP: [125 mg/31.25 mg]/5 mL
- PWDR for SUSP: [250 mg/62.5 mg]/5 mL
UK Trade Name(s)
- Augmentin-Duo
- Co-amoxiclav
UK Availability
Augmentin-Duo (amoxicillin/clavulanate)
- SUSP: 400 mg/57 mg per 5 mL
Co-amoxiclav (amoxicillin/clavulanate)
- PWDR for SUSP: 125 mg/31 mg per 5 mL
- PWDR for SUSP: 250 mg/62 mg per 5 mL
- PWDR for SUSP: 400 mg/57 mg per 5 mL
- TABS: 500 mg/125 mg
Australian Trade Name(s)
- Augmentin
- Augmentin Duo
- Augmentin Duo forte
- Clamoxyl
- Clamoxyl Duo
- Clamoxyl Duo forte
- Clavulin
- Clavulin Duo
- Clavulin Duo forte
- Clavycillin
- Curam
- Curam Duo
- Curam Duo forte
- GA-Amclav
- GA-Amclav forte
- Moxiclav Duo
- Moxiclav Duo forte
Australian Availability
amoxicillin/clavulanate (generic)
- TABS: 500 mg/125 mg
- TABS: 875 mg/125 mg
Augmentin, Clamoxyl, Clavulin, Curam (amoxicillin/clavulanate)
- PWDR for SUSP: 125 mg/31.25 mg per 5 mL
Augmentin Duo, Clamoxyl Duo, Clavulin Duo, Curam Duo (amoxicillin/clavulanate)
- TABS: 500 mg/125 mg
- PWDR for SUSP: 400 mg/57 mg per 5 mL
Augmentin Duo forte, Clavulin Duo forte, Clamoxyl Duo forte, Curam Duo forte, GA-Amclav forte, Moxiclav Duo forte, Clavycillin (amoxicillin/clavulanate)
GA-Amclav, Moxiclav Duo (amoxicillin/clavulanate)
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- Augmentin XR 1000-62.5 MG TB12 [Bottle] (GLAXO SMITH KLINE)
28 mg = $116.69
84 mg = $330.13 - Augmentin 500-125 MG TABS [Bottle] (GLAXO SMITH KLINE)
30 mg = $166.71
90 mg = $482.4 - Augmentin 875-125 MG TABS [Bottle] (DR.REDDY'S LABORATORIES)
20 mg = $169.99
60 mg = $479.97 - Augmentin 250-125 MG TABS [Bottle] (GLAXO SMITH KLINE)
30 mg = $118.99
90 mg = $343.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.